Trial Information
Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment50% Female36%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-PSY-301Data PartnerJohnson & JohnsonCondition StudiedPsychosisMean/Median Age (Years)25.3
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
- 2017-1966 : Psychosis break through antipsychotic maintenance medication: An individual participant data meta-analysis
- 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
- 2016-1005 : Identification of multivariate, clinical patterns predicting treatment response to paliperidone in schizophrenia
- 2015-0676 : Investigating the construct validity of supersensitivity psychosis: An analysis of data from two antipsychotic discontinuation studies